ATE454454T1 - Multifunktionelle und multivalente angiogenese- inhibitoren - Google Patents

Multifunktionelle und multivalente angiogenese- inhibitoren

Info

Publication number
ATE454454T1
ATE454454T1 AT05806365T AT05806365T ATE454454T1 AT E454454 T1 ATE454454 T1 AT E454454T1 AT 05806365 T AT05806365 T AT 05806365T AT 05806365 T AT05806365 T AT 05806365T AT E454454 T1 ATE454454 T1 AT E454454T1
Authority
AT
Austria
Prior art keywords
multifunctional
angiogenesis inhibitors
multivalent
angiogenesis
inhibitors
Prior art date
Application number
AT05806365T
Other languages
English (en)
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Application granted granted Critical
Publication of ATE454454T1 publication Critical patent/ATE454454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05806365T 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese- inhibitoren ATE454454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402635A ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.
PCT/EP2005/011714 WO2006048252A1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
ATE454454T1 true ATE454454T1 (de) 2010-01-15

Family

ID=35592070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05806365T ATE454454T1 (de) 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese- inhibitoren

Country Status (13)

Country Link
US (1) US20070253952A1 (de)
EP (1) EP1814993B1 (de)
JP (1) JP2008527974A (de)
CN (1) CN101065486B (de)
AT (1) ATE454454T1 (de)
AU (1) AU2005300737B2 (de)
BR (1) BRPI0517928A (de)
CA (1) CA2585282A1 (de)
DE (1) DE602005018812D1 (de)
ES (2) ES2325344B1 (de)
PT (1) PT1814993E (de)
RU (1) RU2398878C2 (de)
WO (1) WO2006048252A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580755B2 (en) * 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
WO2010122181A1 (es) * 2009-04-20 2010-10-28 Universidad Autónoma de Madrid Proteínas oligoméricas y sus aplicaciones
US9503931B2 (en) 2009-08-12 2016-11-22 Qualcomm Incorporated Enhancements to the MU-MIMO VHT preamble to enable mode detection
EP2515930A4 (de) * 2009-12-21 2013-04-10 Tty Biopharm Co Ltd Verfahren und zusammensetzungen im zusammenhang mit reduzierter met-phosphorylierung durch aus leukozyten gewonnenes chemotaxin 2 in tumorzellen
EP2420253A1 (de) 2010-08-20 2012-02-22 Leadartis, S.L. Manipulation multifunktioneller und multivalenter Moleküle mit Kollagen-XV-Trimerisationsdomäne
EP2441776A1 (de) 2010-10-15 2012-04-18 Leadartis, S.L. Erzeugung multifunktionaler und multivalenter Polypeptidkomplexe mit Kollagen-XVIII-Trimerisationsdomäne
ES2701445T3 (es) 2010-10-15 2019-02-22 Leadartis S L Generación de complejos polipeptídicos multifuncionales y multivalentes mediante el dominio de trimerización del colágeno XVIII
EP2561888A1 (de) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein enthaltend NC-1 zur Behandlung von Erkrankungen in Bezug auf Angiogenese
WO2017001990A1 (en) * 2015-06-28 2017-01-05 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
CN113912705B (zh) * 2015-07-27 2023-12-22 上海贺普药业股份有限公司 一种肿瘤抑制肽
EP4161957A1 (de) 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Gegen 4-1bb gerichteter multimerer immunmodulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2313251A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
WO2003091447A2 (en) * 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
EP1539941A4 (de) * 2002-08-27 2006-11-29 Adzyme und deren verwendungen
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US8603483B2 (en) * 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses

Also Published As

Publication number Publication date
EP1814993A1 (de) 2007-08-08
ES2325344A1 (es) 2009-09-01
ES2325344B1 (es) 2010-06-09
CN101065486A (zh) 2007-10-31
JP2008527974A (ja) 2008-07-31
US20070253952A1 (en) 2007-11-01
EP1814993B1 (de) 2010-01-06
PT1814993E (pt) 2010-04-12
AU2005300737B2 (en) 2011-05-19
BRPI0517928A (pt) 2008-10-21
ES2339366T3 (es) 2010-05-19
CN101065486B (zh) 2011-08-31
AU2005300737A1 (en) 2006-05-11
DE602005018812D1 (de) 2010-02-25
WO2006048252A1 (en) 2006-05-11
RU2398878C2 (ru) 2010-09-10
RU2007120521A (ru) 2008-12-10
CA2585282A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
EA200970738A1 (ru) Ингибиторы активности akt
ATE454454T1 (de) Multifunktionelle und multivalente angiogenese- inhibitoren
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
PH12022552122A1 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
BRPI0512722A (pt) inibidores de cinase heterocìclica fundida
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
EP3569601A3 (de) N-(phenylsulfonyl)benzamidderivate und verwandte verbindungen als bcl-2-hemmer
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
MX2009012282A (es) Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
CR20230314A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
EA200801430A1 (ru) Производные триазола
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
BR0214799B1 (pt) instalação flutuante para tratamento de hidrocarbonetos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties